# Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis

> **NCT01755507** · PHASE2 · COMPLETED · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 159 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **DRUG:** norUDCA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01755507
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-10
- **Final completion:** 2015-12
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2016-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01755507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01755507, "Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01755507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*